Evaluation of clinical efficacy and safety of adapalene 0·1% gel versus tretinoin 0·025% gel in the treatment of acne vulgaris, with particular reference to the onset of action and impact on quality of life
The DOI matches its Crossref record.
Abstract
A randomized, multicentre, investigator-masked study was conducted in 105 patients with mild to moderate acne vulgaris to compare the efficacy and safety of adapalene 0.1% gel with tretinoin 0.025% gel after three months of treatment, with particular emphasis on reduction in inflammatory lesion counts after one week of treatment and impact on quality of life. In terms of efficacy, adapalene gel was found to be superior to tretinoin gel after one week of treatment, with respect to reduction in inflammatory lesion counts (32% vs. 17%, respectively; P = 0.001), total lesion counts (28% vs. 22%, respectively; P = 0.042) and global severity grade (28% vs. 16%, respectively; P = 0.001). No significant difference between the two treatments was found after 12 weeks of treatment for any of these variables. Evaluation of facial skin tolerance parameters showed significant differences between the two treatments in favour of adapalene for dryness, erythema, immediate and persistent burning and pruritus for at least one time point. One patient in the adapalene group and three patients in the tretinoin group experienced medical events which lead to discontinuation of treatment (skin irritation; NS). Quality of life scores improved more rapidly in the adapalene group than in the tretinoin group, with significant differences (P < 0.05) appearing at week 1 for questions related to problems with partners, close friends or relatives and to skin symptoms. There was also a significantly greater improvement in social and leisure activity in the adapalene group at week 12. Adapalene 0.1% gel reduced inflammatory and total lesion counts more rapidly than tretinoin 0.025% gel, and was also better tolerated. These differences appear to result in an earlier and greater quality of life improvement for the patients receiving adapalene.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Gollnick, H., Cunliffe, W., Berson, D., Dreno, B., Finlay, A., Leyden, J. J., Shalita, A. R., & Thiboutot, D. (2003) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2003.618 · Cited by 817
Basra, M. K. A., Fenech, R., Gatt, R. M., Salek, M. S., & Finlay, A. Y. (2008) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2008.08832.x · Cited by 789
Guidelines of care for acne vulgaris management
Strauss, J. S., Krowchuk, D. P., Leyden, J. J., Lucky, A. W., Shalita, A. R., Siegfried, E. C., Thiboutot, D. M., Van Voorhees, A. S., Beutner, K. A., Sieck, C. K., et al. (2007) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2006.08.048 · Cited by 552
10 Years Experience of the Dermatology Life Quality Index (DLQI)
Lewis, V., & Finlay, A. Y. (2004) · Journal of Investigative Dermatology Symposium Proceedings · doi:10.1111/j.1087-0024.2004.09113.x · Cited by 479
European Evidence‐based (S3) Guidelines for the Treatment of Acne
Nast, A., Dréno, B., Bettoli, V., Degitz, K., Erdmann, R., Finlay, A. Y., Ganceviciene, R., Haedersdal, M., Layton, A., López‐Estebaranz, J. L., et al. (2012) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2011.04374.x · Cited by 426
Metadata
- Authors
- Grosshans, Marks, Mascaro, Torras, Meynadier, Alirezai, Finlay, Soto, Poncet, Verschoore, & Clucas
- Venue
- British Journal of Dermatology
- Publisher
- Oxford University Press (OUP)
- Published
- 1998-09
- Volume
- 139
- Issue
- s52
- Pages
- 26-33
- ISSN
- 0007-0963 (ISSN-L)
- 1365-2133
- OpenAlex
- W2070617828
- Cited by
- 73
- References
- 0
- FWCI
- 5.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evaluation of clinical efficacy and safety of adapalene 0·1% gel versus tretinoin 0·025% gel in the treatment of acne vulgaris, with particular reference to the onset of action and impact on quality of life. https://app.cochat.ai/papers/10.1046/j.1365-2133.1998.1390s2026.x
- The paper
- Grosshans, Marks, Mascaro, Torras, Meynadier, Alirezai, Finlay, Soto, Poncet, Verschoore, & Clucas. (1998). Evaluation of clinical efficacy and safety of adapalene 0·1% gel versus tretinoin 0·025% gel in the treatment of acne vulgaris, with particular reference to the onset of action and impact on quality of life. British Journal of Dermatology. https://doi.org/10.1046/j.1365-2133.1998.1390s2026.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.